Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-01

Clinical Trial Update: A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer [Phase 2]

View source ↗

Summary

Phase II open-label study of BMS-582664 in locally advanced or metastatic hepatocellular carcinoma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BMS-582664

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: COMPLETED | Results posted: 2023-12-01